Home » Topics » Regulatory » EMA

EMA
RSS

Kombiglyze recommended for approval in E.U.

Sep. 27, 2011

European approval recommended for Levemir as add-on to Victoza

Sep. 27, 2011

Positive CHMP opinion on new indications for Xarelto

Sep. 27, 2011

Gilead Sciences announces CHMP's opinion on Eviplera

Sep. 27, 2011

Optimer Pharmaceuticals and Astellas gain CHMP recommendation for Dificid approval

Sep. 26, 2011

Rasitrio recommended for approval in E.U.

Sep. 26, 2011

CHMP issues opinion on Edarbi for essential hypertension

Sep. 26, 2011

EMA begins review of orlistat-containing antiobesity medicines

Sep. 26, 2011

EMA confirms positive benefit-to-risk balance for Multaq

Sep. 23, 2011

EMA committee recommends extending approval of Levemir

Sep. 23, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...